Morgan Stanley Silence Therapeutics PLC Transaction History
Morgan Stanley
- $1.27 Trillion
- Q2 2024
A detailed history of Morgan Stanley transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Morgan Stanley holds 303,993 shares of SLN stock, worth $5.49 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
303,993
Previous 242,770
25.22%
Holding current value
$5.49 Million
Previous $5.24 Million
10.15%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding SLN
# of Institutions
70Shares Held
27.1MCall Options Held
0Put Options Held
0-
Tcg Crossover Management, LLC Palo Alto, CA3.3MShares$59.5 Million9.38% of portfolio
-
Artal Group S.A. Luxembourg, N42.78MShares$50.2 Million3.35% of portfolio
-
Lombard Odier Asset Management (Usa) Corp New York, NY2.41MShares$43.5 Million3.46% of portfolio
-
Redmile Group, LLC San Francisco, CA2.01MShares$36.4 Million2.5% of portfolio
-
Logos Global Management LP San Francisco, CA1.48MShares$26.7 Million2.63% of portfolio
About Silence Therapeutics plc
- Ticker SLN
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,888,400
- Market Cap $649M
- Description
- Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...